Celldex Therapeutics CLDX Change in receivables
Change in receivables at other companies
Other financials
Where this comes from
Reported directly by Celldex Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables.
The official record: Celldex Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Celldex Therapeutics's change in receivables.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Celldex Therapeutics's change in receivables?
- Celldex Therapeutics (CLDX) reported change in receivables of -$1.79M in Q1 2026.
- How has Celldex Therapeutics's change in receivables changed year-over-year?
- Celldex Therapeutics's change in receivables decreased by 590.4% year-over-year, from $364K to -$1.79M.
- What is the long-term trend for Celldex Therapeutics's change in receivables?
- Over 4 years (2021 to 2025), Celldex Therapeutics's change in receivables has grown at a -4.4% compound annual growth rate (CAGR), from -$1.57M to $1.32M.
- What does change in receivables mean?
- Change in total receivables including trade and non-trade receivables.